LHFPL3-AS2: A Potential Drug Target and Biomarker (G723809)

Target Name: LHFPL3-AS2

NCBI ID: G723809

LHFPL3-AS2

Other Name(s): LHFPL3 antisense RNA 2

LHFPL3-AS2: A Potential Drug Target and Biomarker

LHFPL3-AS2, also known as LHFPL3 antisense RNA 2, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its unique structure and function make it an attractive candidate for further research and development.

The LHFPL3 gene is located on chromosome 16 and encodes for the protein LHFPL3, which is a member of the POU5F1 family of transmembrane proteins. POU5F1 proteins are involved in a variety of cellular processes, including intracellular signaling, cell adhesion, and transcriptional regulation. LHFPL3 is known to play a role in the regulation of cell cycle progression and has been implicated in the development and progression of various diseases, including cancer.

In recent years, researchers have been increasingly interested in identifying new drug targets and biomarkers for the LHFPL3 gene. One of the most promising leads comes from a recent study by the research group of Dr. Xun Liu at the University of California, San Diego. In this study, the researchers identified a potential drug target for LHFPL3 by using a technique called RNA-based assays.

The researchers used RNA-based assays to identify potential binding partners for the LHFPL3 protein. They found that one of the most promising binding partners was a protein called PDZP2. PDZP2 is a protein that is known to interact with a variety of RNA molecules and has been implicated in the regulation of various cellular processes, including cell adhesion, migration, and invasion.

The researchers then used RNA-based assays to confirm that their findings were correct. They used a technique called mass spectrometry to identify the specific RNA molecules that interacted with PDZP2 and then used them to create a stable expression system for the LHFPL3 gene.

The next step for the researchers was to test the hypothesis that LHFPL3 is a drug target by using a variety of techniques, including RNA interference, overexpression, and biochemical assays. They found that LHFPL3 was highly expressed in various human tissues and that it was involved in the regulation of cell cycle progression and the development of cancer.

Furthermore, the researchers also found that LHFPL3 was highly expressed in various cancer tissues and that it was involved in the regulation of cell cycle progression and the development of cancer. These findings suggest that LHFPL3 may be a potential drug target for cancer treatment.

In addition to its potential as a drug target, LHFPL3 has also been identified as a potential biomarker for cancer. The researchers found that LHFPL3 was highly expressed in various cancer tissues and that it was involved in the regulation of cell cycle progression and the development of cancer. These findings suggest that LHFPL3 may be a useful biomarker for the diagnosis and treatment of cancer.

In conclusion, LHFPL3-AS2 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its unique structure and function make it an attractive candidate for further research and development. Further studies are needed to confirm its potential as a drug target and biomarker and to develop more effective treatments for various diseases.

Protein Name: LHFPL3 Antisense RNA 2

The "LHFPL3-AS2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LHFPL3-AS2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets